Retail Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Retail Press Releases.

Press releases published on October 5, 2026

BEYYON Rechargeable Hand Warmers with LED Displays: Two Market-Tested Cold-Weather Essentials, Each in a 2-Pack
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
Cerevance Appoints Karl Kieburtz, M.D., M.P.H., as Chief Medical Officer
OnCusp Therapeutics Announces Positive Phase 1b Data Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Resistant Ovarian Cancer (PROC) Presented at Plenary Oral Session of the IGCS 2026 Annual Global Meeting
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
Dillard’s Introduces Hadley Greene x Gianni Bini Fall 2026 Collaboration
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
AGM Group Holdings Inc. Announces Closing of US$11.0 million Private Placement
Fractyl Health, Inc. Class Action Reminder – Robbins LLP Encourages GUTS Investors to Contact the Firm for Information About Their Rights
Kaplan Fox Reminds UWM Holdings Corporation (NYSE: UWMC) Investors to Protect Their Rights Before the Deadline on October 13, 2026
Robbins LLP Urges RYDE Investors with Large Losses to Contact the Firm for Information About the Class Action Against Ryde Group Ltd
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels
Robbins LLP Reminds GDDY Investors of Securities Class Action and October 20, 2026 Lead Plaintiff Deadline
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Satellos Granted Composition of Matter Patent for Forazapadin
BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth
Kaplan Fox Notifies Taboola.com Ltd. (NASDAQ: TBLA) Investors of a Securities Class Action Lawsuit – Deadline is October 20, 2026

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Retail Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.